atrial-natriuretic-factor and apixaban

atrial-natriuretic-factor has been researched along with apixaban* in 1 studies

Other Studies

1 other study(ies) available for atrial-natriuretic-factor and apixaban

ArticleYear
Myocardial interaction of apixaban after experimental acute volume overload.
    The Journal of international medical research, 2022, Volume: 50, Issue:11

    Acute volume overload (AVO) induces early ischemia-like changes in intramyocardial arteries. We investigated whether the Factor Xa (FXa) inhibitor apixaban interacts with the myocardium early after AVO.. Fifty-five syngeneic Fisher rats underwent surgical abdominal aortocaval fistula to induce AVO. Among them, 17 rats were treated with apixaban (10 mg/kg/day). The myocardial outcome was studied using histological analysis and by measuring atrial natriuretic peptide (ANP) and matrix metalloprotease 9 (MMP9) gene expression.. After 3 days, the total number of intramyocardial arteries was significantly increased in the. Apixaban interacts with intramyocardial arteries in the left and right ventricles after AVO and ANP and MMP9 expression levels increased. Thus, the myocardial effect of Factor Xa inhibition needs to be monitored after AVO.

    Topics: Animals; Atrial Natriuretic Factor; Factor Xa; Heart Failure; Matrix Metalloproteinase 9; Myocardium; Rats; Water-Electrolyte Imbalance

2022